BD Venture

BD Venture Limited, a Venture Capital Company, is an outcome of relentless effort from a group of leaders of the financial and entrepreneurial ecosystems of Bangladesh with a view to promoting innovative and potential seed, early & growth stage entrepreneurs & enterprises to pave their expansion through facilitating investment, consultancy & other relevant services. We are capable to address and accommodate the undulations of a venture and tailor our & the investee enterprise’s shape to adapt with a perspective approach. We have adopted innovative ways of investment for those entrepreneurs or enterprises for who the doors of the conventional financing institutions are hardly open.

7 past transactions

E-Desh

Series B in 2021
E-Desh is an E-Commerce Logistics Company that provides integrated logistic solutions with experience, capabilities, functional expertise, technological embedment.

Esho Shikhi

Pre Seed Round in 2019
Eshosikhi.com is an one stop online platform providing students with 360 degree solution.Students of Bangladesh can take preparation on K12 education, university entrance exam and job preparation in this platform.

Beetles Cyber Security

Seed Round in 2019
Beetles is an ISO 27001 certified offensive cybersecurity consultancy firm. We specialize in a manual and exploitative PenTesting assessments of a company’s IT environment. With a hacker-powered, platform-led approach, we simulate a real-world attack scenario on applications, APIs, network and cloud infrastructure, and network devices. Our Manual PenTests, by skilled and experienced ethical hackers, are smaller, faster, more agile, and easily integrates with any development environment and process. While our PenTest_as_a_Service (PTaaS) ensures continuous coverage of the scope through a properly defined, structured approach and collaboration with your internal team.

cWork Microjob Limited

Pre Seed Round in 2018
cWork is a platform where you can hire thousands of workers to complete small tasks like data collection, survey, and content writing. You can create virtually any kinds of task that you think can be completed from a mobile app.

Zantrik

Pre Seed Round in 2018
"Zantrik" is a Transparent and Convenient vehicle maintenance platform developed with Process innovation, Technology and Artificial Intelligence. Traditional way of vehicle maintenance is unstructured and fragmented. It lacks transparency, reliability and standard, worldwide. Zantrik is streamlining this by developing a connected system that offers transparency, convenience and benefits to every stakeholder in this ecosystem. We are developing this system in a way can be scaled across geographical boundary. With this system, vehicle owners, garages and suppliers, all are connected to a single platform. From placing a maintenance request by vehicle owners till delivery by garage, the full execution life cycle is maintained in fully automated way, and each of these stakeholders gets clear visibility about what's going on, and can ensure value for money/profitability at the end of the day with the right flow of information.

RenaMed Biologics

Venture Round in 2006
RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.

ViaCyte

Venture Round in 2006
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.